110 related articles for article (PubMed ID: 29531130)
21. Adjuvant chemotherapy with carboplatin and taxane compared with single drug carboplatin in early stage epithelial ovarian carcinoma.
Skírnisdóttir I; Lindborg K; Sorbe B
Oncol Rep; 2007 Nov; 18(5):1249-56. PubMed ID: 17914581
[TBL] [Abstract][Full Text] [Related]
22. Taxane-sensitivity of ovarian carcinomas previously treated with paclitaxel and carboplatin.
Ueda Y; Enomoto T; Matsuzaki S; Kobayashi E; Kimura T; Yoshino K; Fujita M; Tsutsui T; Kimura T
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1411-6. PubMed ID: 23515753
[TBL] [Abstract][Full Text] [Related]
23. Prediction of Chemotherapy Response With Platinum and Taxane in the Advanced Stage of Ovarian and Uterine Carcinosarcoma: A Clinical Implication of In vitro Drug Resistance Assay.
Matsuo K; Bond VK; Im DD; Rosenshein NB
Am J Clin Oncol; 2010 Aug; 33(4):358-63. PubMed ID: 19875949
[TBL] [Abstract][Full Text] [Related]
24. The association of taxane resistance genes with the clinical course of ovarian carcinoma.
Ehrlichova M; Mohelnikova-Duchonova B; Hrdy J; Brynychova V; Mrhalova M; Kodet R; Rob L; Pluta M; Gut I; Soucek P; Vaclavikova R
Genomics; 2013 Aug; 102(2):96-101. PubMed ID: 23542236
[TBL] [Abstract][Full Text] [Related]
25. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
26. Predictive value of ATP7b, BRCA1, BRCA2, PARP1, UIMC1 (RAP80), HOXA9, DAXX, TXN (TRX1), THBS1 (TSP1) and PRR13 (TXR1) genes in patients with epithelial ovarian cancer who received platinum-taxane first-line therapy.
Pontikakis S; Papadaki C; Tzardi M; Trypaki M; Sfakianaki M; Koinis F; Lagoudaki E; Giannikaki L; Kalykaki A; Kontopodis E; Saridaki Z; Malamos N; Georgoulias V; Souglakos J
Pharmacogenomics J; 2017 Dec; 17(6):506-514. PubMed ID: 27779244
[TBL] [Abstract][Full Text] [Related]
27. Clinical impact of high mobility group box 1 protein in epithelial ovarian cancer.
Paek J; Lee M; Nam EJ; Kim SW; Kim YT
Arch Gynecol Obstet; 2016 Mar; 293(3):645-50. PubMed ID: 26305032
[TBL] [Abstract][Full Text] [Related]
28. Leptomeningeal carcinomatosis after major remission to taxane-based front-line therapy in patients with advanced breast cancer.
Kosmas C; Malamos NA; Tsavaris NB; Stamataki M; Stefanou S; Gregoriou A; Rokana S; Vartholomeou M; Antonopoulos MJ
J Neurooncol; 2002 Feb; 56(3):265-73. PubMed ID: 12061734
[TBL] [Abstract][Full Text] [Related]
29. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
Brown J; Shvartsman HS; Deavers MT; Ramondetta LM; Burke TW; Munsell MF; Gershenson DM
Gynecol Oncol; 2005 May; 97(2):489-96. PubMed ID: 15863149
[TBL] [Abstract][Full Text] [Related]
30. Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles.
Murakami R; Matsumura N; Brown JB; Wang Z; Yamaguchi K; Abiko K; Yoshioka Y; Hamanishi J; Baba T; Koshiyama M; Mandai M; Yamada R; Konishi I
Gynecol Oncol; 2016 Apr; 141(1):49-56. PubMed ID: 27016229
[TBL] [Abstract][Full Text] [Related]
31. Bowel resection at the time of primary debulking for epithelial ovarian carcinoma: outcomes in patients treated with platinum and taxane-based chemotherapy.
Estes JM; Leath CA; Straughn JM; Rocconi RP; Kirby TO; Huh WK; Barnes MN
J Am Coll Surg; 2006 Oct; 203(4):527-32. PubMed ID: 17000397
[TBL] [Abstract][Full Text] [Related]
32. Is there a taxane-free interval that predicts response to taxanes as a later-line treatment of recurrent ovarian or primary peritoneal cancer?
McCourt C; Dessie S; Bradley AM; Schwartz J; Brard L; Dizon DS
Int J Gynecol Cancer; 2009 Apr; 19(3):343-7. PubMed ID: 19407557
[TBL] [Abstract][Full Text] [Related]
33. Taxane containing regimens for metastatic breast cancer.
Ghersi D; Wilcken N; Simes J; Donoghue E
Cochrane Database Syst Rev; 2003; (3):CD003366. PubMed ID: 12917963
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors in epithelial ovarian cancer: A population-based study.
Chang LC; Huang CF; Lai MS; Shen LJ; Wu FL; Cheng WF
PLoS One; 2018; 13(3):e0194993. PubMed ID: 29579127
[TBL] [Abstract][Full Text] [Related]
35. Predictive value of microtubule associated proteins tau and stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy.
Wosnitzer MS; Domingo-Domenech J; Castillo-Martin M; Ritch C; Mansukhani M; Petrylack DP; Benson MC; McKiernan JM; Cordon-Cardo C
J Urol; 2011 Nov; 186(5):2094-100. PubMed ID: 21944130
[TBL] [Abstract][Full Text] [Related]
36. Transducin-like enhancer of split 3 regulates proliferation of melanoma cells via histone deacetylase activity.
Ogawa M; Yaginuma T; Nakatomi C; Nakajima T; Tada-Shigeyama Y; Addison WN; Urata M; Matsubara T; Watanabe K; Matsuo K; Sato T; Honda H; Hikiji H; Watanabe S; Kokabu S
Oncotarget; 2019 Jan; 10(3):404-414. PubMed ID: 30719233
[TBL] [Abstract][Full Text] [Related]
37. TP53 gene status and human papilloma virus infection in response to platinum plus taxane-based chemotherapy of epithelial ovarian carcinomas.
Malisic E; Jankovic R; Jakovljevic K; Radulovic S
J BUON; 2011; 16(4):701-7. PubMed ID: 22331725
[TBL] [Abstract][Full Text] [Related]
38. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
39. The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1).
Murakami R; Matsumura N; Michimae H; Tanabe H; Yunokawa M; Iwase H; Sasagawa M; Nakamura T; Tokuyama O; Takano M; Sugiyama T; Sawasaki T; Isonishi S; Takehara K; Nakai H; Okamoto A; Mandai M; Konishi I
Gynecol Oncol; 2019 May; 153(2):312-319. PubMed ID: 30853361
[TBL] [Abstract][Full Text] [Related]
40. Generation of a TLE3 heterozygous knockout human embryonic stem cell line using CRISPR-Cas9.
Bara AM; Messana A; Herring A; Hazelbaker DZ; Eggan K; Barrett LE
Stem Cell Res; 2016 Sep; 17(2):441-443. PubMed ID: 27879221
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
